Quick Answer
RenovoRx, Inc. reported Stockholders Equity of $5.42 million for fiscal year 2025.
RenovoRx, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $5.42M | +21.1% |
| 2024 | $4.48M | +49.3% |
| 2023 | $3.00M | -51.3% |
| 2022 | $6.16M | -59.8% |
| 2021 | $15.35M | +204.7% |
| 2020 | -$14.66M | -34.1% |
| 2019 | -$10.93M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.08M | +14.2% | -24.1% |
| June 30, 2025 | $10.64M | +14.8% | -19.1% |
| March 31, 2025 | $13.16M | +644.6% | +193.8% |
| December 31, 2024 | $4.48M | +249.3% | -36.7% |
| September 30, 2024 | $7.07M | +117750.0% | -23.7% |
| June 30, 2024 | $9.27M | +680.5% | +424.7% |
| March 31, 2024 | $1.77M | -45.7% | +158.9% |
| December 31, 2023 | -$3.00M | -148.7% | -50100.0% |
- RenovoRx, Inc. showed an increase of +21.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, RenovoRx, Inc.’s stockholders equity has grown by 149.6% (from -$10.93 million to $5.42 million).
- The most recent figure is from RenovoRx, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: